Clinical trial
Study Evaluating ReFacto in Hemophilia A
NCT00038909 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00038909 |
|---|---|
| Title | Study Evaluating ReFacto in Hemophilia A |
| Official title | Factor VIII Mutation Testing Program in Previously Untreated Patients (PUPs) With Hemophilia A Participating in ReFacto® Study |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Hemophilia A |
| Intervention type | Drug |
| Interventions | BDDrFVII |
| Enrollment | 103 |
| Start date | Sep 1, 1994 |
| Primary completion | May 1, 2001 |
| Completion | May 1, 2001 |
| First posted | Jun 7, 2002 |
| Last update posted | Feb 8, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: